• Japanese
  • Korean
  • Chinese
Cover Image

U.S. Markets for Oncology-Related Diagnostic Ultrasound, Minimally Biopsy, and Tissue Screening Products

Cancer is the second-leading cause of death in the United States (U.S.) after heart disease. It is estimated that nearly 1.7 million people in the country will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. In the fight against cancer, diagnostic ultrasound imaging, minimally invasive biopsy, and tissue screening are among the methods that allow physicians to detect malignancies at their earliest and most treatable stages.

In 2012, approximately 92.0 million oncology-related diagnostic ultrasound, minimally invasive biopsy, and tissue screening procedures were performed in the U.S. Together, these procedures generated approximately $1.1 billion in corresponding product sales; it is expected that during the forecast period covered by this report, sales of diagnostic ultrasound, minimally invasive biopsy, and tissue screening products for oncology-related indications will increase at a compound annual rate of 3.9%, reaching nearly $1.4 billion in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic ultrasound, minimally invasive biopsy, and tissue screening products arena.

Covered topics in this report include an overview of cancer in the U.S. including discussions of the different forms of the disease; automated and semi-automated tissue screening technologies; capacitive micromachined ultrasonic transducers; contrast-enhanced ultrasound; core needle biopsy systems; diagnostic ultrasound systems; Doppler and tissue harmonic imaging; fine-needle aspiration; human papilloma virus testing systems; minimally invasive biopsy; Papanicolaou smear testing systems; photoacoustic imaging; risk factors for cancer development; statistics covering new cancer cases, cancer prevalence, and cancer-related deaths; tissue elastography; and vacuum-assisted biopsy systems; among others

Table of Contents

EXECUTIVE SUMMARY

  • i. New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
  • ii. Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Procedures
  • iii. Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products
    • a. Oncology-Related Diagnostic Ultrasound Systems Market Segment
    • b. Minimally Invasive Biopsy Systems Market Segment
    • c. Tissue Screening Systems Market Segment
  • iv. Methodology
  • Exhibit ES-1: Estimated New Cases, Prevalence,and Deaths for Selected Types of Cancer
  • Exhibit ES-2: Oncology-Related Diagnostic Ultrasound,Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017
  • Exhibit ES-3: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products, Combined Market Forecast, 2012-2017
  • Exhibit ES-4: Oncology-Related Diagnostic Ultrasound Systems, Market Forecast, 2012-2017
  • Exhibit ES-5: Minimally Invasive Biopsy Products, Market Forecast, 2012-2017
  • Exhibit ES-6: Tissue Screening Products, Market Forecast, 2012-2017

1. CANCER STATISTICS UPDATE

  • 1.1. Acquired Capabilities of Cancer Cells
  • 1.2. Cataloging Genomic Alterations Involved in the Development of Cancer
  • 1.3. Risk Factors Associated with the Development of Cancer
  • 1.4. Cancer Staging
  • 1.5. New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
  • 1.6. Clinical and Statistical Data for Selected Types of Cancer
    • 1.6.1. Brain and Other Nervous System Cancers
      • 1.6.1.1. Etiology
      • 1.6.1.2. Epidemiology
    • 1.6.2. Breast Cancer
      • 1.6.2.1. Etiology
      • 1.6.2.2. Epidemiology
    • 1.6.3. Colorectal Cancer
      • 1.6.3.1. Etiology
      • 1.6.3.2. Epidemiology
    • 1.6.4. Kidney/Renal Pelvis Cancer
      • 1.6.4.1. Etiology
      • 1.6.4.2. Epidemiology
    • 1.6.5. Leukemia
      • 1.6.5.1. Etiology
      • 1.6.5.2. Epidemiology
    • 1.6.6. Lung/Bronchus Cancer
      • 1.6.6.1. Etiology
      • 1.6.6.2. Epidemiology
    • 1.6.7. Lymphoma
      • 1.6.7.1. Etiology
      • 1.6.7.2. Epidemiology
    • 1.6.8. Melanoma
      • 1.6.8.1. Etiology
      • 1.6.8.2. Epidemiology
    • 1.6.9. Oral Cavity and Pharyngeal Cancers
      • 1.6.9.1. Etiology
      • 1.6.9.2. Epidemiology
    • 1.6.10. Ovarian Cancer
      • 1.6.10.1. Etiology
      • 1.6.10.2. Epidemiology
    • 1.6.11. Pancreatic Cancer
      • 1.6.11.1. Etiology
      • 1.6.11.2. Epidemiology
    • 1.6.12. Prostate Cancer
      • 1.6.12.1. Etiology
      • 1.6.12.2. Epidemiology
    • 1.6.13. Thyroid Cancer
      • 1.6.13.1. Etiology
      • 1.6.13.2. Epidemiology
    • 1.6.14. Urinary Bladder Cancer
      • 1.6.14.1. Etiology
      • 1.6.14.2. Epidemiology
    • 1.6.15. Uterine Cancer
      • 1.6.15.1. Etiology
      • 1.6.15.2. Epidemiology
  • Exhibit 1-1: Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer
  • Exhibit 1-2: Brain and Other Nervous System Cancers, Facts And Figures
  • Exhibit 1-3: Breast Cancer, Facts And Figures
  • Exhibit 1-4: Colorectal Cancer, Facts And Figures
  • Exhibit 1-5: Kidney/Renal Pelvis Cancers, Facts And Figures
  • Exhibit 1-6: Leukemia, Facts and Figures
  • Exhibit 1-7: Lung/Bronchus Cancer, Facts And Figures
  • Exhibit 1-8: Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-9: Non-Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-10: Melanoma of the Skin, Facts and Figures
  • Exhibit 1-11: Oral Cavity and Pharyngeal Cancers, Facts and Figures
  • Exhibit 1-12: Ovarian Cancer, Facts and Figures
  • Exhibit 1-13: Pancreatic Cancer, Fact and Figures
  • Exhibit 1-14: Prostate Cancer, Facts And Figures
  • Exhibit 1-15: Thyroid Cancer, Fact and Figures
  • Exhibit 1-16: Urinary Bladder Cancer, Fact and Figures
  • Exhibit 1-17: Cancer of the Uterine Corpus, Facts and Figures
  • Exhibit 1-18: Cancer of the Uterine Cervix, Facts and Figures

2. U.S. MARKETS FOR ONCOLOGY-RELATED DIAGNOSTIC ULTRASOUND, MINIMALLY INVASIVE BIOPSY, AND TISSUE SCREENING PRODUCTS

  • 2.1. Diagnostic Ultrasound Systems, Market Analysis
    • 2.1.1. Technologies
      • 2.1.1.1. Doppler Imaging
      • 2.1.1.2. Tissue Harmonic Imaging
      • 2.1.1.3. Tissue Elastography
      • 2.1.1.4. Contrast-Enhanced Ultrasound
    • 2.1.2. Procedure Volumes
    • 2.1.3. Products
    • 2.1.4. Market Forecast
    • 2.1.5. Competitive Analysis
  • 2.2. Minimally Invasive Biopsy Systems, Market Analysis
    • 2.2.1. Technologies
      • 2.2.1.1. Core Needle/Fine Needle/Multipurpose Tool-Assisted Biopsy
      • 2.2.1.2. Vacuum-Assisted Biopsy
    • 2.2.2. Procedure Volumes
    • 2.2.3. Products
    • 2.2.4. Market Forecast
    • 2.2.5. Competitive Analysis
  • 2.3. Tissue Screening, Market Analysis
    • 2.3.1. Technologies
    • 2.3.2. Procedure Volumes
    • 2.3.3. Products
    • 2.3.4. Market Forecast
    • 2.3.5. Competitive Analysis
  • Exhibit 2-1: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening, Combined Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-2: Oncology-Related Diagnostic Ultrasound, Minimally Invasive Biopsy, and Tissue Screening Products, Combined Market Forecast, 2012-2017
  • Exhibit 2-3: Oncology-Related Diagnostic Ultrasound, Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-4: 2014, Selected Diagnostic Ultrasound Systems
  • Exhibit 2-5: Oncology-Related Diagnostic Ultrasound Systems, Market Forecast, 2012-2017
  • Exhibit 2-6: 2012, Oncology-Related Diagnostic Ultrasound Systems Market, Share by Supplier
  • Exhibit 2-7: Minimally Invasive Biopsy, Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-8: 2014, Selected Minimally Invasive Biopsy Products
  • Exhibit 2-9: Minimally Invasive Biopsy Products, Market Forecast, 2012-2017
  • Exhibit 2-10: 2012, Minimally Invasive Biopsy Products Market, Share by Supplier
  • Exhibit 2-11: Tissue Screening, Procedure Volumes Forecast, 2012-2017
  • Exhibit 2-12: 2014, Selected Tissue Screening Products
  • Exhibit 2-13: Tissue Screening Products, Market Forecast, 2012-2017
  • Exhibit 2-14: 2012, Tissue Screening Products Market, Share by Supplier

3. COMPANY PROFILES

  • 3.1. Analogic Corporation
  • 3.2. Bard Biopsy Systems/ Bard Peripheral Vascular, Inc./ C.R. Bard, Inc
  • 3.3. Becton, Dickinson and Company
  • 3.4. CareFusion Corporation
  • 3.5. Fujifilm SonoSite, Inc./Fujifilm Medical Systems USA, Inc./ Fujifilm Holdings America Corporation/Fujifilm
  • 3.6. GE Healthcare, Inc./General Electric Company
  • 3.7. Hitachi Aloka Medical America/Hitachi Aloka Medical/ Hitachi Medical/Hitachi
  • 3.8. Hologic, Inc.
  • 3.9. Mammotome/Devicor Medical Products, Inc.
  • 3.10. Mindray Medical USA Corporation/Mindray Medical International LTD
  • 3.11. Philips Healthcare, Inc./Royal Philips NV
  • 3.12. Qiagen NV
  • 3.13. Samsung Medison/Samsung Electronics America, Inc./ Samsung Electronics Co., LTD/Samsung
  • 3.14. Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • 3.15. Toshiba America Medical Systems, Inc./Toshiba Corporation

APPENDIX: COMPANY LISTING

Show More
RELATED REPORTS
* U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems
  • Published:
  • Oct 01, 2014
  • USD 4750
  • 180 pages

* Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments (HPLC, Mass Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, Oncology) & by End User - Global Forecast to 2019
  • Published:
  • Sep 30, 2014
  • USD 4650
  • 198 Pages

* Advances in Imaging and Marker Technology for Oncology Diagnosis
  • Published:
  • Sep 28, 2014
  • USD 6500
  • 56 Pages

* Interventional Oncology Devices | US | 2015 | Market Analysis
  • Published:
  • Aug 29, 2014
  • USD 6495

* Molecular Diagnostics Market by Application (Infectious Disease, Oncology, Genetics, Microbiology), Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, Laboratories), Product (Instruments, Reagent, Service, Software) - Global Forecasts to 2018
  • Published:
  • Jun 17, 2014
  • USD 4650
  • 299 Pages

* MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players
  • Published:
  • May 26, 2014
  • USD 3500
  • 281 Pages

* MediPoint: Companion Diagnostic Tests in Oncology - APAC Analysis and Market Forecasts
  • Published:
  • May 21, 2014
  • USD 4450
  • 446 Pages

* MediPoint: Companion Diagnostic Tests in Oncology - EU Analysis and Market Forecasts
  • Published:
  • May 21, 2014
  • USD 4450
  • 489 Pages

* MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts
  • Published:
  • May 21, 2014
  • USD 4450
  • 408 Pages

* MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts
  • Published:
  • May 21, 2014
  • USD 4450
  • 423 Pages

Browse more Ultra Sound Market Research Reports

Pricing